119 related articles for article (PubMed ID: 32776753)
1. Effect of BRAF/MEK Inhibition on Epithelioid Glioblastoma with BRAFV600E Mutation: a Case Report and Review of the Literature.
Li Y; Yang S; Hao C; Chen J; Li S; Kang Z; Kang X; Zhang H; Li W
Clin Lab; 2020 Aug; 66(8):. PubMed ID: 32776753
[TBL] [Abstract][Full Text] [Related]
2. Epithelioid glioblastoma with microglia features: potential for novel therapy.
Nakagomi N; Sakamoto D; Hirose T; Takagi T; Murase M; Nakagomi T; Yoshimura S; Hirota S
Brain Pathol; 2020 Nov; 30(6):1119-1133. PubMed ID: 32687679
[TBL] [Abstract][Full Text] [Related]
3. Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy.
Kanemaru Y; Natsumeda M; Okada M; Saito R; Kobayashi D; Eda T; Watanabe J; Saito S; Tsukamoto Y; Oishi M; Saito H; Nagahashi M; Sasaki T; Hashizume R; Aoyama H; Wakai T; Kakita A; Fujii Y
Acta Neuropathol Commun; 2019 Jul; 7(1):119. PubMed ID: 31345255
[TBL] [Abstract][Full Text] [Related]
4. Effective treatment of a BRAF V600E-mutant epithelioid glioblastoma patient by vemurafenib: a case report.
Lin Z; Xu H; Yang R; Li Z; Zheng H; Zhang Z; Peng J; Zhang X; Qi S; Liu Y; Huang G
Anticancer Drugs; 2022 Jan; 33(1):100-104. PubMed ID: 34232949
[TBL] [Abstract][Full Text] [Related]
5. BRAF
Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
[TBL] [Abstract][Full Text] [Related]
6. [Progress of anti-tumor study based on BRAF].
Yan GR; Xu ZJ; Wang HY; Zhu WL
Yao Xue Xue Bao; 2012 Dec; 47(12):1567-74. PubMed ID: 23460959
[TBL] [Abstract][Full Text] [Related]
7. [Clinicopathological features for epithelioid glioblastoma: A newly defined tumor by the 2016 World Health Organization Classification of Tumors of the Central Nervous System].
Li J; Ling X; Lai M; Hu Q; Shan C; Cai L
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Apr; 43(4):398-402. PubMed ID: 29774876
[TBL] [Abstract][Full Text] [Related]
8. Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma.
Matsumura N; Nakajima N; Yamazaki T; Nagano T; Kagoshima K; Nobusawa S; Ikota H; Yokoo H
Neuropathology; 2017 Feb; 37(1):58-63. PubMed ID: 27302309
[TBL] [Abstract][Full Text] [Related]
9. Proteomic Profiling of BRAFV600E Mutant Colon Cancer Cells Reveals the Involvement of Nucleophosmin/c-Myc Axis in Modulating the Response and Resistance to BRAF Inhibition by Vemurafenib.
Grbčić P; Fučkar Čupić D; Gamberi T; Kraljević Pavelić S; Sedić M
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34201061
[TBL] [Abstract][Full Text] [Related]
10. BRAF-MEK Inhibition Is Effective in BRAFV600E-Mutant Papillary Craniopharyngioma.
Cancer Discov; 2023 Sep; 13(9):1960. PubMed ID: 37477404
[TBL] [Abstract][Full Text] [Related]
11. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
12. The oxidoreductase p66Shc acts as tumor suppressor in BRAFV600E-transformed cells.
Furlan T; Khalid S; Nguyen AV; Günther J; Troppmair J
Mol Oncol; 2018 Jun; 12(6):869-882. PubMed ID: 29624862
[TBL] [Abstract][Full Text] [Related]
13. Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma.
Lim-Fat MJ; Song KW; Iorgulescu JB; Andersen BM; Forst DA; Jordan JT; Gerstner ER; Reardon DA; Wen PY; Arrillaga-Romany I
J Neurooncol; 2021 May; 152(3):515-522. PubMed ID: 33646525
[TBL] [Abstract][Full Text] [Related]
14. A case of osteoclast-like giant cell-rich epithelioid glioblastoma with BRAF V600E mutation.
Funata N; Nobusawa S; Yamada R; Shinoura N
Brain Tumor Pathol; 2016 Jan; 33(1):57-62. PubMed ID: 26602910
[TBL] [Abstract][Full Text] [Related]
15. Phosphoproteomics of MAPK inhibition in BRAF-mutated cells and a role for the lethal synergism of dual BRAF and CK2 inhibition.
Parker R; Clifton-Bligh R; Molloy MP
Mol Cancer Ther; 2014 Jul; 13(7):1894-906. PubMed ID: 24825855
[TBL] [Abstract][Full Text] [Related]
16. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.
Kleinschmidt-DeMasters BK; Aisner DL; Foreman NK
Am J Surg Pathol; 2015 Apr; 39(4):528-40. PubMed ID: 25581727
[TBL] [Abstract][Full Text] [Related]
17. Dabrafenib and trametinib in BRAFV600E mutated glioma.
Brown NF; Carter T; Kitchen N; Mulholland P
CNS Oncol; 2017 Oct; 6(4):291-296. PubMed ID: 28984141
[TBL] [Abstract][Full Text] [Related]
18. The Significance of
Prieto R; Barrios L; Ebrat-Mancilla E; Martín P; Tejerina E
Int J Surg Pathol; 2024 Jun; 32(4):649-666. PubMed ID: 37743598
[TBL] [Abstract][Full Text] [Related]
19. 17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.
Joshi SS; Jiang S; Unni E; Goding SR; Fan T; Antony PA; Hornyak TJ
PLoS One; 2018; 13(2):e0191264. PubMed ID: 29481571
[TBL] [Abstract][Full Text] [Related]
20. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.
Queirolo P; Picasso V; Spagnolo F
Cancer Treat Rev; 2015 Jun; 41(6):519-26. PubMed ID: 25944484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
